BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 18650169)

  • 1. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.
    Coon D; Gokhale AS; Burton SA; Heron DE; Ozhasoglu C; Christie N
    Clin Lung Cancer; 2008 Jul; 9(4):217-21. PubMed ID: 18650169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CyberKnife radiosurgery for stage I lung cancer: results at 36 months.
    Brown WT; Wu X; Fayad F; Fowler JF; Amendola BE; García S; Han H; de la Zerda A; Bossart E; Huang Z; Schwade JG
    Clin Lung Cancer; 2007 Sep; 8(8):488-92. PubMed ID: 17922973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
    Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy.
    Nawara C; Rendl G; Wurstbauer K; Lackner B; Rettenbacher L; Datz L; Studnicka M; Sedlmayer F; Pirich C
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):191-201. PubMed ID: 22402822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
    Satoh Y; Nambu A; Onishi H; Sawada E; Tominaga L; Kuriyama K; Komiyama T; Marino K; Aoki S; Araya M; Saito R; Maehata Y; Oguri M; Araki T
    Eur J Radiol; 2012 Nov; 81(11):3530-4. PubMed ID: 22178287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An analysis of 20 consecutive patients treated with stereotactic body radiotherapy on Novalis Tx(®) for stage I non-small-cell lung cancer].
    Guillerme F; Clavier JB; Schumacher C; Falcoz PE; Bourrhala K; Santelmo N; Hassler S; Schott R; Quoix E; Massard G; Noël G
    Cancer Radiother; 2013; 17(4):272-81. PubMed ID: 23712043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
    Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment [18F]fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome.
    Lee DS; Kim YS; Yoo IeR; Kang YN; Kim SJ; Oh JK; Kim YK; Wang YP; Park JG; Kang JH; Han DH; Ahn MI; Lee KY
    Lung Cancer; 2013 May; 80(2):172-8. PubMed ID: 23489556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region.
    Siddiqui F; Patel M; Khan M; McLean S; Dragovic J; Jin JY; Movsas B; Ryu S
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1047-53. PubMed ID: 19327895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.
    Geiger GA; Kim MB; Xanthopoulos EP; Pryma DA; Grover S; Plastaras JP; Langer CJ; Simone CB; Rengan R
    Clin Lung Cancer; 2014 Jan; 15(1):79-85. PubMed ID: 24238934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of stereotactic radiotherapy for stage I non-small cell lung cancer using a novel irradiation technique: patient self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner.
    Onishi H; Kuriyama K; Komiyama T; Tanaka S; Sano N; Marino K; Ikenaga S; Araki T; Uematsu M
    Lung Cancer; 2004 Jul; 45(1):45-55. PubMed ID: 15196734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
    Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early results of CyberKnife image-guided robotic stereotactic radiosurgery for treatment of lung tumors.
    Brown WT; Wu X; Wen BC; Fowler JF; Fayad F; Amendola BE; García S; De La Zerda A; Huang Z; Schwade JG
    Comput Aided Surg; 2007 Sep; 12(5):253-61. PubMed ID: 17957532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of early non-small cell lung cancer, stage IA, by image-guided robotic stereotactic radioablation--CyberKnife.
    Brown WT; Wu X; Amendola B; Perman M; Han H; Fayad F; Garcia S; Lewin A; Abitbol A; de la Zerda A; Schwade JG
    Cancer J; 2007; 13(2):87-94. PubMed ID: 17476136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC).
    Zimmermann FB; Geinitz H; Schill S; Thamm R; Nieder C; Schratzenstaller U; Molls M
    Acta Oncol; 2006; 45(7):796-801. PubMed ID: 16982542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT).
    Dunlap NE; Larner JM; Read PW; Kozower BD; Lau CL; Sheng K; Jones DR
    J Thorac Cardiovasc Surg; 2010 Sep; 140(3):583-9. PubMed ID: 20478576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.
    Lanni TB; Grills IS; Kestin LL; Robertson JM
    Am J Clin Oncol; 2011 Oct; 34(5):494-8. PubMed ID: 20805737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries.
    Baumann P; Nyman J; Lax I; Friesland S; Hoyer M; Rehn Ericsson S; Johansson KA; Ekberg L; Morhed E; Paludan M; Wittgren L; Blomgren H; Lewensohn R
    Acta Oncol; 2006; 45(7):787-95. PubMed ID: 16982541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC).
    Hof H; Muenter M; Oetzel D; Hoess A; Debus J; Herfarth K
    Cancer; 2007 Jul; 110(1):148-55. PubMed ID: 17516437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.